Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 in Locally Advanced/Metastatic Solid Tumors
NCT06826313Phase 1Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRT-106 in solid tumor, sponsored by Guangzhou Virotech Pharmaceutical. Primary endpoint: Safety and Tolerability at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
VRT-106
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06826313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826313.